Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Lung Neoplasms 1

Interventions

Cisplatin 18Docetaxel 17Cetuximab 12Carboplatin 12Magnetic Resonance Spectroscopy 10pembrolizumab 9Radiotherapy 9Paclitaxel 8Erlotinib Hydrochloride 8Trastuzumab 7Gemcitabine 7Biopsy 7Specimen Handling 6Radiotherapy, Intensity-Modulated 6Radiotherapy, Conformal 5Radiosurgery 5Fluorodeoxyglucose F18 5Chemotherapy, Adjuvant 5Capecitabine 5Vorinostat 4Taxes 4Sorafenib 4Nivolumab 4Bevacizumab 4sargramostim 3Radiation 3Platinum 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Salivary Gland Neoplasms × talactoferrin alfa × Clear all
NCT01528137 2016-08-02

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

Phase 1 Terminated
4 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡